Oxyntomodulin |
Catalog No.GC16969
One-Click Copy Product Info
|
Oxyntomodulin is a 37-amino-acid peptide hormone that simultaneously activates both the glucagon-like peptide-1 receptor and the glucagon receptor, thereby regulating appetite, energy expenditure, and blood glucose levels.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 62340-29-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Oxyntomodulin is a 37-amino-acid peptide hormone that simultaneously activates both the glucagon-like peptide-1 receptor and the glucagon receptor, thereby regulating appetite, energy expenditure, and blood glucose levels[1]. Oxyntomodulin is a product of the glucagon precursor proglucagon and is produced and released by intestinal L-cells after processing by prohormone convertase [2]. Oxyntomodulin holds potential for the treatment of diabetes and obesity[3-4].
In vitro, pretreatment of SH-SY5Y cells with Oxyntomodulin (10–1000nM) for 1 hour, followed by stimulation with glutamate (100–150μM) or hydrogen peroxide (150μM) for 24 hours, significantly increased cell viability and reduced cell death induced by glutamate excitotoxicity and oxidative stress[5].
In vivo, Oxyntomodulin (4–25μg per mouse) was administered intravenously or intraperitoneally to 8–24-week-old C57BL/6J mice to simulate the regulation of liver circadian rhythms by food intake. When administered early in the circadian cycle, Oxyntomodulin acutely induced the expression of core liver clock genes Per1/2 and reset the rhythmic expression of hepatic clock genes (Per2, Dbp) and metabolism-related genes (Foxo1, Pdk4, Slc2a2), resulting in phase delays or reduced amplitude[6]. In Wistar rats weighing 180–400g, intraperitoneal injection of Oxyntomodulin (3–100nmol/kg) dose-dependently inhibited fasting-induced refeeding and dark-phase feeding without delaying gastric emptying. Additionally, peripheral injection of Oxyntomodulin significantly reduced fasting plasma ghrelin levels and increased c-fos immunoreactivity in the hypothalamic arcuate nucleus (ARC), suggesting that it suppresses appetite by activating ARC neurons[7].
References:
[1] Holst JJ, Rosenkilde MM. Oxyntomodulin - past, present and future. Peptides. 2025 Jun;188:171393.
[2] Holst JJ, Albrechtsen NJW, Gabe MBN, et al. Oxyntomodulin: Actions and role in diabetes. Peptides. 2018 Feb;100:48-53.
[3] Zhihong Y, Chen W, Qianqian Z, et al. Emerging roles of oxyntomodulin-based glucagon-like peptide-1/glucagon co-agonist analogs in diabetes and obesity. Peptides. 2023 Apr;162:170955.
[4] Wynne K, Field BC, Bloom SR. The mechanism of action for oxyntomodulin in the regulation of obesity. Curr Opin Investig Drugs. 2010 Oct;11(10):1151-7.
[5] Li Y, Wu KJ, Yu SJ, et al. Neurotrophic and neuroprotective effects of oxyntomodulin in neuronal cells and a rat model of stroke. Exp Neurol. 2017 Feb;288:104-113.
[6] Landgraf D, Tsang AH, Leliavski A, et al. Oxyntomodulin regulates resetting of the liver circadian clock by food. Elife. 2015 Mar 30;4:e06253.
[7] Dakin CL, Small CJ, Batterham RL, et al. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology. 2004 Jun;145(6):2687-95.
| Cell experiment [1]: | |
Cell lines | SH-SY5Y cells (human neuroblastoma cell line) |
Preparation Method | SH-SY5Y cells were serum-starved (with 0.5% serum) overnight before pretreatment with various concentrations of Oxyntomodulin (1–1000nM) for 1h. Cells were then exposed to glutamate (100–150μM) or H₂O₂ (150μM) for 24h. |
Reaction Conditions | 1–1000nM; 1 hours |
Applications | Oxyntomodulin dose-dependently increased cell viability and protected against glutamate-induced excitotoxicity and oxidative stress. In SH-SY5Y cells, Oxyntomodulin (1–1000nM) effectively reduced glutamate (100mM)-mediated cell death, while higher concentrations (100nM) were required to counteract glutamate (150mM) toxicity. |
| Animal experiment [2]: | |
Animal models | Adult male Wistar rats |
Preparation Method | Rats received intraperitoneal (i.p.) injections of Oxyntomodulin at doses of 3-100nmol/kg. For acute studies, food intake was measured after 24-hour fasting or during the dark phase. For chronic studies, rats received twice-daily i.p. injections of Oxyntomodulin (50nmol/kg) for 7 days. |
Dosage form | 3-100nmol/kg; i.p. |
Applications | Peripheral Oxyntomodulin administration dose-dependently inhibited both fast-induced and dark-phase food intake. Oxyntomodulin (30-100nmol/kg) significantly reduced cumulative food intake for up to 24 hours. Chronic administration for 7 days decreased body weight gain and adiposity (reduced white and brown adipose tissue mass) compared to pair-fed controls, suggesting effects beyond reduced caloric intake. |
References: | |
| Cas No. | 62340-29-8 | SDF | |
| Canonical SMILES | CC[C@]([C@@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/ | ||
| Formula | C192H295N59O60S | M.Wt | 4421.86 |
| Solubility | Soluble to 1 mg/ml in Water | Storage | Desiccate at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 226.1 μL | 1.1307 mL | 2.2615 mL |
| 5 mM | 45.2 μL | 226.1 μL | 452.3 μL |
| 10 mM | 22.6 μL | 113.1 μL | 226.1 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 6 reference(s) in Google Scholar.)